Reunion Neuroscience is a venture backed clinical-stage biopharmaceutical company developing novel therapeutics for neuropsychiatric disorders.

Reunion Neuroscience

Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds. NASDAQ:REUN 


We are thrilled to share our recent article in Psychiatric Times highlighting the clinical development of RE104, a proprietary, serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #postpartumdepression. Thank you to Reunion team members, Robert Alexander, Jasna Hocevar-Trnka, Nathan Bryson, PhD and Beatrix Taylor for their incredible work on this article: https://bit.ly/4eA0eZn

Reunion now has the fuel on board to move boldly forward with RE104 into Phase 2 programs in postpartum depression and adjustment disorder in cancer patients.  Thank you very much to our top tier investing syndicate for linking arms with us to help bring forward a new and meaningful treatment option to address the worldwide mental health crisis.  Onward!

Looking forward to SXSW and speaking about new treatments for postpartum depression with Daniel Goldberg Greg Mayes and Melissa Whippo!

We are excited to announce the publication of the results of preclinical studies in ACS Chemical Neuroscience demonstrating the potential of RE104 for development in depressive disorders. Reunion is advancing RE104, a proprietary, clinical-stage serotonergic #psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders, beginning with #postpartumdepression. Read the press release: https://bit.ly/3wFJkY4

#MMHWeek2024 is an opportunity to raise awareness of #MaternalMentalHealth as a significant unmet need. Mental health conditions are the leading underlying cause of pregnancy-related death, with preventable deaths accounting for more than 80 percent. In our mission to address the worldwide mental health crisis, Reunion is advancing RE104 for underserved #mentalhealth disorders, beginning with #postpartumdepression.

Domain Not Resolving

HSTS

Content Delivery Network

reCAPTCHA

Cloudflare CDN

Cloudflare

Google Universal Analytics

reCAPTCHA v2

U.S. Server Location

Cloudflare Bot Manager

General Counsel and Corporate Secretary

Curtis Weber

Founder and Chairman

Joseph Moral

Chief Scientific Officer

Nathan Bryson

Vice President Medical Affairs

Aviva Asnis-Alibozek

VP, Clinical Development & Regulatory Affairs

Beatrix Taylor

Sr Director CMC

Anthony Grenier

Administrative Manager

Leigh Bracken

Chief Financial Officer

Edward Smith

Business Management

Gregory Mayes

Clinical Trial Associate

Jennifer Hernandez

Mark Pollack

Chief Medical Officer

Ronan Levy

Co-Founder

Venture Capital Funded Companies (Top 10K)

Ontario Companies With Fewer Than 100 Employees (Top 10K)

Pharmaceutical Acquired Companies With Less Than $500M in Revenue

Ontario Acquired Companies With Fewer Than 100 Employees

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.
Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

MPM Capital

Novo Holdings

Series A - Reunion Neuroscience

Toronto

Ontario

Canada

North America

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Reunion Neuroscience Inc. Announces First Patient Dosed in

MPM BioImpact-owned Reunion raises $103M, one of the largest rounds for a psychedelic biotech

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial

Reunion Neuroscience's $103 Million Series A Financing Round – Global Legal Chronicle

Reunion Neuroscience’s $103 Million Series A Financing Round

United States

United Kingdom

Europe

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 5:20 AM	7603eb32
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 18, 2024 8:15 AM	eb43a208
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	8729d3c3
crunchbase profile	general	Oct 30, 2024 8:05 AM	bc8a28c4
li profile	general	Jul 18, 2024 5:20 AM	0fc24d78
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	2433ed48
peers	general	Jul 18, 2024 5:20 AM	0e6dcd5a
news basic	general	Jul 18, 2024 5:20 AM	8d4428ec
bundesanzeiger	filings
financials download nd	financials
private financials	financials

REUN

COM:REUNIONNEURO

Reunion Neuroscience